General Information of Drug (ID: DMOML9Q)

Drug Name
Pancrecarb Drug Info
Synonyms Pancrelipase (Digestive Care)
Indication
Disease Entry ICD 11 Status REF
Pancreatic malfunction DC30-DC3Z NDA filed [1]
Cross-matching ID
TTD Drug ID
DMOML9Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Chymotrypsin (CTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Liprotamase DMNF4UH Cystic fibrosis CA25 Phase 3 [3]
CM-AT DMLMN2F Attention deficit hyperactivity disorder 6A05.Z Phase 3 [4]
POP-1 DMVTKCX Solid tumour/cancer 2A00-2F9Z Investigative [2]
JBP-1 DM0KMPN Solid tumour/cancer 2A00-2F9Z Investigative [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Liprotamase DMNF4UH Cystic fibrosis CA25 Phase 3 [3]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [5]
Pyroglutamic Acid DMROZUA Discovery agent N.A. Investigative [5]
Acanthus ilicifolius Linn DMZDFRI Discovery agent N.A. Investigative [6]
6-Deoxy-Alpha-D-Glucose DM9HBY5 Discovery agent N.A. Investigative [5]
Acarbose Derived Hexasaccharide DMS9COH Discovery agent N.A. Investigative [5]
Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam DMMY542 Discovery agent N.A. Investigative [7]
Hydroxycitric acid DMY0A9E Discovery agent N.A. Investigative [8]
Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen DM4IXUQ Discovery agent N.A. Investigative [9]
Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen DMHV14R Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Orlistat DMRJSP8 Obesity 5B81 Approved [10]
Dalbavancin DMGMNH3 Bacterial infection 1A00-1C4Z Approved [11]
Liprotamase DMNF4UH Cystic fibrosis CA25 Phase 3 [3]
MS-1819 DM35YFC Exocrine pancreatic insufficiency DC35.1 Phase 1/2 [12]
AZM-131 DMLCSRF Obesity 5B81 Terminated [13]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [5]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane DMY6FUD Discovery agent N.A. Investigative [5]
B-Nonylglucoside DM48VJR Discovery agent N.A. Investigative [14]
METHOXYUNDECYLPHOSPHINIC ACID DMY0O7X Discovery agent N.A. Investigative [14]
Daio-Orengedokuto (DOT) DM3M652 Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Chymotrypsin (CTR) TT7MRGU NOUNIPROTAC Modulator [2]
Pancreatic alpha-amylase (AMY2A) TTCGSZ4 AMYP_HUMAN Modulator [1]
Pancreatic triacylglycerol lipase (PNLIP) TTXMY0J LIPP_HUMAN Modulator [1]

References

1 Clinical pipeline report, company report or official report of Digestive Care.
2 US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
3 Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
4 Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92.
7 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
8 Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82.
9 Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Pfizer. Product Development Pipeline. March 31 2009.
12 Clinical pipeline report, company report or official report of AzurRx.
13 US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor.
14 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15 Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.